Insight

Jul 29, 2024, 13:24

Gautam Mehta et al. summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki – FDA Oncology

FDA Oncology shared a post on X about a paper titled “FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations” published in The Oncologist Journal.

Authors: Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh.

Gautam Mehta et al. summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki - FDA Oncology

“OCE’s Gautam Mehta and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer – via The Oncologist Journal.”

Source: FDA Oncology/X

Anup K Amatya cancer Claudia P Miller fam-trastuzumab deruxtecan-nxki FDA Approval Summary FDA Oncology Gautam Mehta Harpreet Singh Jeanne F Zirkelbach Jiang Liu Julia A Beaver Lili Pan Marc Theoret Mirat Shah Nam Atiqur Rahman non small cell lung cancer OCE OncoDaily Oncology Pallavi S Mishra-Kalyani Paul Kluetz Paz J Vellanki Richard Pazdur Stephanie L Aungst The Oncologist Journal Yi Ren Yuzhuo Pan

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage